StockData
ALX Oncology Holdings Inc logo

ALX Oncology Holdings Inc (ALXO) stock

ALXONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 3/30
$1.00+0.00 (+0.50%)

Close on Nov 17, 2026Market cap $138.97MP/E –Yield –

ALX Oncology enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

ALX Oncology's enterprise value was $26.28M on Nov 11, 2026, against $22.89M a year earlier. Over the last 5 years it ranged from -$89.27M to $677.09M, with a median of $63.60M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$26.28M+162.0%
2025Dec 31, 2025$10.03M–
2024Dec 31, 2024-$50.66M-111.7%
2023Dec 29, 2023$432.32M+148.0%
2022Dec 30, 2022$174.32M-64.0%
2021Dec 31, 2021$484.90M-83.5%
2020Dec 31, 2020$2.94B–

More ALX Oncology figures

See a number that looks wrong?